Shockwave Medical Inc. (SWAV)
(Delayed Data from NSDQ)
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWO
SmileDirectClub (SDC) Q4 Earnings Beat, Gross Margin Down
by Zacks Equity Research
SmileDirectClub (SDC) delivers an improved bottom line and cash flows in the fourth quarter despite a reduction in revenues.
Omnicell (OMCL) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Omnicell (OMCL) delivers earnings and revenues in the fourth quarter exceeding the previously revised outlook amid macroeconomic challenges.
Alcon (ALC) Q4 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
Alcon (ALC) reports impressive CER growth in net sales across all segments in the fourth quarter amid a challenging macroeconomic environment.
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWG
Wall Street Analysts Think Shockwave Medical (SWAV) Could Surge 28.8%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Shockwave Medical (SWAV) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Shockwave Medical's (SWAV) Q4 Earnings Top, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Shockwave Medical (SWAV) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 274.75% and 1.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q4 Earnings on Feb 16: WST, SWAV & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat macro headwinds. Let's see how WST, SWAV, AMN, ITGR and PACB are likely to fare this time.
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
What's in Store for West Pharmaceutical (WST) in Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and the bottom lines.
Are Options Traders Betting on a Big Move in ShockWave (SWAV) Stock?
by Zacks Equity Research
Investors need to pay close attention to ShockWave (SWAV) stock based on the movements in the options market lately.
Shockwave Medical (SWAV) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Shockwave Medical (SWAV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for discovery business, and informatics franchise.
Shockwave Medical (SWAV) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Shockwave Medical (SWAV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.
Intuitive Surgical (ISRG) Falls Following Q4 Earnings Miss
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect healthy demand for procedures, partially offset by lower system sales and unfavorable currency. Procedure volume in China suffers.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
ShockWave Medical (SWAV) Posts Solid Preliminary Q4 Revenues
by Zacks Equity Research
ShockWave Medical's (SWAV) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its U.S. Coronary business.
Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome
by Zacks Equity Research
Shockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool.
Can Shockwave Medical (SWAV) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Shockwave Medical (SWAV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should iShares Morningstar SmallCap Growth ETF (ISCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCG
Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RFG